Abstract 84P
Background
Therapy with Immune Checkpoint Inhibitors (ICI) is standard of care for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC). Still there are conflicting data about efficacy and safety, in regard to immune-related adverse event (irAEs) in the elderly patients. The aim of this study is to analyze efficacy and safety in the elderly patients with NSCLC undergoing treatment with ICI.
Methods
286 patients with NSCLC treated with at least one cycle of ICI have been included in the analysis. Clinical data were analyzed using binomial regression, and Chi-squared test.
Results
irAEs occurred in 63 out of 286 patients: gastrointestinal 14 (4.9%), endocrine 8 (2.8%), dermatologic 11 (3.8%), neurologic 6 (2.1%), cardiac 2 (0.7%), pulmonary 21 (7.3%), renal 1 (0.3%) and hepatic 5 (1.7%). According to CTCAE v5, 6 (9.5%) were Grade 1, 24 (38.1%) Grade 2, 30 (47.6%) Grade 3 and 3 (4.8%) Grade 4. Incidence of immune related adverse was not related to the age (p=0.3982). The probability of irAEs was correlated with the CIRS-G score (Cumulative Illness Rating Scale for Geriatrics) (p=0.00947). Between the different age-groups there was no difference in outcomes at 3-months (p=0.129) and 6-months (p=0.775) between the age groups.
Conclusions
Our analysis showed that patients older than 75 years didn’t experienced more toxicities. We observed a higher probability to experience irAES with higher CIRS-G score. This result underlines the importance to assess the comorbidities and the functional status of older patients with a geriatric assessment prior to oncological treatment. We could not find a difference in the outcomes at 3-months and 6-months between the age groups suggesting no significant difference in the efficacy of the immunotherapy. In conclusion, our analysis suggests that treatments with ICI’s is feasible and safe in older patients with NSCLC.
Legal entity responsible for the study
The authors.
Funding
HFR Fribourg.
Disclosure
V. Dougoud-Chauvin: Financial Interests, Personal, Advisory Board: Exact sciences. A. Curioni-Fontecedro: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Novartis, Amgen, Roche, Takeda, Janssen; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Non-Financial Interests, Personal, Leadership Role: Swiss Academy for Clinical Cancer Research (SAKK); Non-Financial Interests, Personal, Principal Investigator, of clinical trials: Roche; Non-Financial Interests, Personal, Principal Investigator, Clinical Trials: Takeda, MSD, Bristol Myers Squibb, Amgen, AstraZeneca; Non-Financial Interests, Personal, Principal Investigator, Clinical trials: iTEOS Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract